Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding recent announcements and the Year-End-report (Q4)
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that a video interview by BioStock has been released with CEO Sten R. Sörensen, commenting on the recently published year-end report for 2023, the status of the ongoing Phase II-trial of CS1 in PAH and the related Expanded Access Program as well as the upcoming subscription of series 3 (TO3) warrantsWatch here: Two thirds of patients suitable for compassionate use according to investigators in Phase II-trial